|1.||Bray, Mark R: 6 articles (01/2013 - 06/2010)|
|2.||Fletcher, Graham C: 4 articles (01/2013 - 06/2010)|
|3.||Diamond, Jennifer R: 3 articles (01/2013 - 06/2010)|
|4.||Eckhardt, S Gail: 3 articles (01/2013 - 06/2010)|
|5.||Pitts, Todd M: 3 articles (01/2013 - 06/2010)|
|6.||Arnott, Jamie: 2 articles (01/2013 - 02/2011)|
|7.||Tentler, John J: 2 articles (01/2013 - 06/2010)|
|8.||Sidor, Carolyn F: 2 articles (01/2013 - 01/2011)|
|9.||Brokx, Richard D: 2 articles (01/2013 - 01/2011)|
|10.||Zhang, Shuhong: 2 articles (07/2011 - 08/2010)|
01/01/2011 - "ENMD-2076 inhibited the growth in vitro of a wide range of human solid tumor and hematopoietic cancer cell lines with IC(50) values ranging from 0.025 to 0.7 μmol/L. "
06/01/2010 - "All three of the patient-derived xenografts tested were sensitive to treatment with ENMD 2076 as measured by tumor growth inhibition. "
06/01/2010 - "In the HT-29 xenograft model, ENMD-2076 induced initial tumor growth inhibition followed by regression. "
06/01/2010 - "Additionally, three patient-derived xenografts from primary and metastatic sites were treated with ENMD-2076 (100 mg/kg) and assessed for tumor growth inhibition. "
01/01/2011 - "These results indicate that ENMD-2076 is a well-tolerated, orally active multitarget kinase inhibitor with a unique antiangiogenic/antiproliferative profile and provides strong preclinical support for use as a therapeutic for human cancers. "
|2.||Colorectal Neoplasms (Colorectal Cancer)
06/01/2010 - "Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models."
06/01/2010 - "This in vivo study was designed to investigate the efficacy of ENMD-2076, a small-molecule kinase inhibitor with activity against the Aurora kinases A and B, and several other tyrosine kinases linked to cancer, including vascular endothelial growth factor receptor 2, cKit, and fibroblast growth factor receptor 1, against murine xenograft models of human colorectal cancer (CRC). "
|3.||Ovarian Neoplasms (Ovarian Cancer)
02/15/2011 - "ENMD-2076 was well tolerated, had a linear pharmacokinetic profile, and showed promising antitumor activity, particularly in ovarian cancer. "
01/01/2011 - "Several phase 1 studies involving ENMD-2076 have been recently completed, and the compound is currently being evaluated in a phase 2 clinical trial in patients with platinum-resistant ovarian cancer."
01/01/2013 - "ENMD-2076 has activity in platinum-resistant ovarian cancer, and observed toxicities were similar to other PO kinase inhibitors. "
01/01/2013 - "ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer."
|4.||Breast Neoplasms (Breast Cancer)
01/01/2013 - "Within the triple-negative breast cancer subset, cell lines with a p53 mutation and increased p53 expression were more sensitive to the cytotoxic and proapoptotic effects of ENMD-2076 exposure than cell lines with decreased p53 expression. "
01/01/2013 - "Twenty-nine breast cancer cell lines were exposed to ENMD-2076 and the effects on proliferation, apoptosis, and cell-cycle distribution were evaluated. "
01/01/2013 - "ENMD-2076 showed antiproliferative activity against breast cancer cell lines, with more robust activity against cell lines lacking estrogen receptor expression and those without increased HER2 expression. "
01/01/2013 - "ENMD-2076 exhibited robust anticancer activity against models of triple-negative breast cancer and the candidate predictive biomarkers identified in this study may be useful in selecting patients for Aurora kinase inhibitors in the future."
01/01/2013 - "The purpose of this study was to evaluate the antitumor activity of the Aurora and angiogenic kinase inhibitor ENMD-2076 against preclinical models of breast cancer with identification of candidate predictive biomarkers. "
07/01/2011 - "From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma."
08/01/2010 - "We investigated the activity of ENMD-2076 against multiple myeloma (MM) cells in vitro and in vivo. "
08/01/2010 - "Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma."
01/01/2011 - "ENMD-2076 was also shown to induce regression or complete inhibition of tumor growth in vivo at well-tolerated doses in tumor xenograft models derived from breast, colon, melanoma, leukemia, and multiple myeloma cell lines. "
05/01/2012 - "ENMD-2076 is a multi-kinase inhibitor, with activity against Aurora A kinase, FLT3, c-KIT, c-FMS and VEGFR-2 and -3. It appears to be tolerable, exhibits favorable pharmacokinetic profiles and has activity in patients with acute myeloid leukemia and multiple myeloma. "
|2.||aurora kinase (aurora A kinase)
|3.||Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
|5.||Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)
|7.||Biological Markers (Surrogate Marker)
|8.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|10.||Ovarian epithelial cancer
|1.||Heterologous Transplantation (Xenotransplantation)